An Open-label, Dose Escalation, Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of TAK-676 as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Advanced or Metastatic Solid Tumors
NCT #
NCT04420884
Condition(s)
Colorectal Cancer, Head and Neck Cancer, Solid Tumor
Molecular Target(s)
STING
Drug Classification(s)
Immunotherapy, targeted
Agents(s)
Prior treatment with PSMA-targeted CAR-T cell therapy Prior treatment with PSMA-CD3 engaging bispecific antibodies Prior treatment with systemic immunotherapeutic agents, including anti-CTLA4, anti-PD-1, anti-PD-L1, or other checkpoint inhibiting therapeutic antibodies within 28 days prior to the start of study drug
Phase(s)
I
Mechanism of Action
TAK-676 is a synthetic cyclic dinucleotide (CDN) exhibiting highly selective binding and activation of STING pathway.
Purpose
- How much of the study drug can be given with an acceptable level of side effects
- About the safety and tolerability of the study drug alone and in combination with Pembrolizumab
- How proteins that indicate the status of your immune system are affected with the use of the study drug alone and in combination with Pembrolizumab
- If the study drug alone and in combination with Pembrolizumab prevents or delays tumor growth or shrinks existing tumors
- How quickly the study drug is removed from your bloodstream
Location
MCD
Similar Trials
Discover more trials like this.
Trial Number
Mechanism of Action
Drug Classifications
Target
Conditions
Publications
24-08
RMC-6291 is a tri-complex inhibitor of the active GTP-bound state of the mutated KRASG12C protein RMC-6236 is a RASMULTI(ON) inhibitor
Molecular Targeted Therapy, Small Molecule
KRAS
Solid Tumor
Yes
24-05
BG-68501 is a CDK2 Inhibitor
CDK2 Inhibitor, Molecular Targeted Therapy
CDK2
Solid Tumor
No
JIT-MCLA-129-CL01
MCLA-129, a Human Anti-EGFR and Anti-c-MET Bispecific Antibody
Immunotherapy
EGFR, MET
Esophageal Cancer, Gastric/GEJ Cancer, Head and Neck Cancer, Lung Cancer (NSCLC)
No
Connect With Us
Whether you want to give a spark of hope or you are looking for it, we are here to help. If you have any questions or concerns, please contact us here.